german stock information letter - updatesorry something get wrong. here again (google translater :) :
yesterday announced the management of Sirona Biochem (WKN: A0RM6R) that you want to significantly expand the research and development expenses. This is according to a statement from the CEO Dr. Howard Verrico, "a short-term expected prepayment under a licensing agreement for our new skin whitening-Wirkstoffver-bond". This is obviously a hint, hint!
Reminder: in the recent corporate presentation, management of Sirona Biochem is based on an upfront payment of USD 90 million (115 million CAD) for this substance from. The market value of the company is currently only 34 million CAD.
A new project of Sirona Biochem aims at the effective treatment of overgrown scars from (keloid scars). About 10 to 15 percent of all wounds are affected by this type of scar. The current treatment options of keloid scars to show very limited results, which is why there is an enormous need with regard to new drugs here.
According to a recent report by Persistence Market Research is the global scar treatment market going to grow at a CAGR of 10.3 percent from $ 16.0 billion in 2015 to 31.9 billion in the year 2022nd
The scientific team led by Dr. Graldine Deliencourt-Godefroy will focus in the context of another project on a promising drug for the treatment of common acne. The global acne market is expected to 2020 sales of $ 4.4 billion reached (Technavio, 2016).
Work on the keloid scars project have already started - the first results are expected in the fourth quarter of 2016th The development program for the acne-project is scheduled to begin later this quarter. The management of Sirona Biochem is looking for the in vitro studies for partners for this innovative compounds.